Back to News
Market Impact: 0.3

We Did The Math SPYX Can Go To $58

SPYXZTSREGNDOCNDAQ
Analyst EstimatesAnalyst InsightsCompany Fundamentals
We Did The Math SPYX Can Go To $58

An ETF Channel analysis indicates an implied analyst target price of $57.72 for the SPDR S&P 500 Fossil Fuel Reserves Free ETF (SPYX), suggesting a 10.88% upside from its recent $52.05 trading price. This projection is significantly influenced by key underlying holdings such as Zoetis (ZTS), Regeneron (REGN), and Healthpeak Properties (DOC), which analysts project to have over 30% upside. The report advises that these analyst targets warrant further investor scrutiny.

Analysis

An analysis of the SPDR S&P 500 Fossil Fuel Reserves Free ETF (SPYX) reveals a weighted average implied analyst target price of $57.72, suggesting a 10.88% upside from its recent price of $52.05. This potential is largely driven by specific holdings with substantial projected gains, including Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), and Healthpeak Properties (DOC), which have average analyst targets implying upsides of 32.81%, 32.73%, and 30.93%, respectively. However, the analysis is qualified by a significant note of caution, questioning whether these high price targets are justified or potentially outdated, which could make them precursors to future downgrades. This inherent uncertainty, reflected in the 'cautious' tone signal, underscores the need for investors to look beyond the headline upside figure and conduct deeper due diligence on the underlying components and the assumptions driving these analyst forecasts.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

mixed

Sentiment Score

0.10

Ticker Sentiment

DOC0.70
NDAQ0.00
REGN0.70
SPYX0.40
ZTS0.70

Key Decisions for Investors

  • Investors considering SPYX should recognize that its 10.88% implied upside is heavily concentrated in a few key holdings, warranting a closer look at the health and outlook of Zoetis, Regeneron, and Healthpeak Properties.
  • The substantial ~30% upside cited for ZTS, REGN, and DOC should be treated as a signal for further research to validate the underlying assumptions and catalysts, rather than a direct buy signal.
  • Given the explicit warning about overly optimistic or outdated targets, it is prudent to verify the recency of analyst ratings for the ETF's key drivers and monitor for any potential price target revisions.